StrongDecrease
All-cause mortality
Canagliflozin → All-cause mortality
Canagliflozin → All-cause mortality
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Canagliflozin reduces cardiovascular and kidney risks in type 2 diabetes
Key finding
Canagliflozin reduced the risk of major adverse cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94])
This study evaluated the effects of canagliflozin on cardiovascular and kidney outcomes in individuals with type 2 diabetes, finding a reduction in major adverse cardiovascular events.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Extended (5–20+ y)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Canagliflozin
Study type
RCTs
Follow-up
Extended (5–20+ y)
Primary outcome
Composite cardiovascular events (CV death
Comparator
Placebo, Placebo
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effects of canagliflozin on cardiovascular and kidney outcomes in individuals with type 2 diabetes, finding a reduction in major adverse cardiovascular events.
Clinical relevance
These findings are significant as they suggest that canagliflozin may be an effective option for reducing cardiovascular risks in patients with type 2 diabetes, a population that is already at high risk for heart disease. Understanding the benefits of this medication can help healthcare providers make informed treatment decisions to improve patient outcomes.
Keep in mind
Effectiveness of canagliflozin for other outcomes remains unclear. Study results may not be generalizable to all populations with type 2 diabetes. Limited information on long-term effects of canagliflozin.
Published in
Journal Reference
Publication details and source links for this paper.
Abhinav S, Amir R, Abdulaziz J, et al. Canagliflozin and Cardiovascular and Kidney Outcomes in Type 2 Diabetes. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2024;13(3):e031586. doi:10.1161/JAHA.123.031586
Save this study and add notes to your research library.
Main Effects
Canagliflozin reduced the risk of composite cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94]).
No treatment effect heterogeneity was observed for hospitalization for heart failure.
No treatment effect heterogeneity was observed for cardiovascular death.
No treatment effect heterogeneity was observed for end-stage kidney disease.
No treatment effect heterogeneity was observed for all-cause mortality.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Canagliflozin and All-cause mortality, Cardiovascular death, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 2 more.
This study contributes evidence to
Primary intervention
Canagliflozin
Primary outcomes
- All-cause mortality
- Cardiovascular death
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
5
Evidence pairs
51
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Cardiovascular death
Canagliflozin → Cardiovascular death
Canagliflozin → Cardiovascular death
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Canagliflozin → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Canagliflozin → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
Hospitalization for heart failure
Canagliflozin → Hospitalization for heart failure
Canagliflozin → Hospitalization for heart failure
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
Nephropathy progression
Canagliflozin → Nephropathy progression
Canagliflozin → Nephropathy progression
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Canagliflozin reduced major adverse cardiovascular events by 16%.
- No significant treatment effects were observed for heart failure or mortality.
- Study included diverse participants with type 2 diabetes.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Individuals at high risk for cardiovascular events.
Keep in Mind
- Results may not apply to younger populations or those without diabetes.
- Further research is needed to explore long-term effects.
- The study did not assess the impact of canagliflozin on quality of life.
Between the Lines
- Effectiveness of canagliflozin for other outcomes remains unclear.
- Study results may not be generalizable to all populations with type 2 diabetes.
- Limited information on long-term effects of canagliflozin.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Cardiovascular Outcomes, SGLT2 Inhibitors and Cardiovascular death.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Cardiovascular death Evidence Hub
All studies measuring Cardiovascular death
1 studies
outcome_hubMeasures Cardiovascular death as a key outcome.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
1 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
1 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Canagliflozin and All-cause mortality
Intervention: CanagliflozinOutcome: All-cause mortality
1 results
All studies on Canagliflozin and Cardiovascular death
Intervention: CanagliflozinOutcome: Cardiovascular death
1 results
All studies on Canagliflozin
Intervention: Canagliflozin
1 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
1 results
All studies measuring Cardiovascular death
Outcome: Cardiovascular death
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve cardiovascular outcomes?
Emerging Evidence
SGLT2 Inhibitors appears to improve Cardiovascular Outcomes.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study
- 2
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does SGLT2 Inhibitors improve kidney function?
Emerging Evidence
Current evidence does not show a clear benefit of SGLT2 Inhibitors for Kidney Function.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Nephropathy progression
EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 6 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Canagliflozin improve cardiovascular death?
Emerging Evidence
Canagliflozin appears to improve Cardiovascular death.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Cardiovascular death
EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Canagliflozin improve hospitalization for heart failure?
Emerging Evidence
Canagliflozin appears to improve Hospitalization for heart failure.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hospitalization for heart failure
EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Canagliflozin may reduce myocardial fibrosis in high-risk type 2 diabetesHbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsSemaglutide improves cardiorenal outcomes in high-risk diabetes patientsIntensive glycemic control may lower cardiovascular events in some diabetes patientsCanagliflozin with metformin reduces cardiovascular risk in T2DM
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.